Skye Bioscience, Inc.
SKYENext catalyst
Nimacimab injection
Obesity
Get an email about SKYE's next catalysts
Track Skye Bioscience (SKYE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
SKYE Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Nimacimab injection Phase 2 Est. Readout (CBeyond)
Estimated primary completion for Nimacimab injection trial (NCT06577090) in Obesity. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Nimacimab injection
Obesity
SBI-100 Ophthalmic Emulsion
Primary Open Angle Glaucoma
Nimacimab
Obesity
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nimacimab injection | Phase 2 | Obesity | - | - |
SBI-100 Ophthalmic Emulsion | Phase 2 | Primary Open Angle Glaucoma | - | - |
Nimacimab | Phase 2 | Obesity | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Skye Bioscience, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Skye Bioscience, Inc.'s (SKYE) pipeline across Phase 2. Its lead program is Nimacimab injection (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Skye Bioscience, Inc.'s next FDA catalyst?→
Skye Bioscience, Inc.'s (SKYE) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SKYE biotech catalysts?→
Add SKYE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Skye Bioscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.